Skip to main content
. 2020 Sep 1;12(9):2483. doi: 10.3390/cancers12092483

Figure 2.

Figure 2

ATO/Lena inhibited proliferation and downregulated Kaposi sarcoma herpes virus (KSHV) latent transcripts and proteins in ex vivo treated ascites-derived BC-3 and BCBL-1 cells. (a) Cell proliferation of ascites-derived BC-3 (left) or BCBL-1 cells (right) following ex vivo treatment with ATO and/or Lena for 24, 48, 72, and 96 h. Results are presented as percent of control, plotted as mean ± SD, and represent an average of three independent experiments. (b) Immunoblot analysis of KSHV latent proteins LANA-1 and LANA-2 in ascites-derived BC-3 (left) or BCBL-1(right) cells treated ex vivo for 48 h with ATO, Lena, or their combination. Densitometry histograms represent an average of 3 independent experiments. Uncropped blots of Figure 2b are shown in Figure S5 (c) Real-time quantitative PCR analysis of transcript levels of KSHV latent genes v-FLIP and v-Cyclin in ascites-derived BC-3 (left) or BCBL-1(right), 48 h post treatment with ATO, Lena, or the ATO/Lena combination. Results represent the average of 3 independent experiments. (*) indicates p < 0.05; (**) indicates p < 0.01.